Ec145 clinical trial

Phase Study of EC1Alone Versus EC145Docetaxel Versus Docetaxel. Current practice in clinical oncology is to utilize multidrug combinations instead of. This combination of improvements justified the clinical evaluation of EC0489).

Clinical Trial, Phase I Research Support, Non-U.S. Folate targeting - , the free encyclopedia EC1also represents the first FA-drug conjugate to be evaluated in clinical trials, and it is currently (2009) being tested in a multi-national randomized Phase. Reducing Undesirable Hepatic Clearance of a Tumor-Targeted. Journal of Clinical Oncology, 20ASCO Annual Meeting Abstracts.

Is targeting folate receptors using folic acid really useful in the. 99mTc- Etarfolatide: Properties, Clinical Use, and Future Potential of Folate. This is a Phase clinical trial to evaluate the efficacy and safety of the combination of EC1and pegylated liposomal doxorubicin (PLD).

Profile of vintafolide (EC145) and its use in the treatment of platinu

Phase II PRECEDENT Trial of Vintafolide in Platinum-Resistant. During a phase I trial of EC1(a folate-targeted vinca alkaloid conjugate. It is a small molecule drug conjugate.

Profile of vintafolide (EC145) and its use in the treatment of.
This is a Phase II clinical trial evaluating the benefit from therapy with vintafolide in participants with advanced ovarian and endometrial cancers. We use a variety of different targeting ligands, linker systems, and drug payloads to create a pipeline of novel SMDC candidates for clinical development.

Enrollment is ongoing in the pivotal Phase III PROCEED clinical trial with. EC1demonstrated clinical activity with a good toxicity profile in this population. Study of Vintafolide (MK-810 EC145) in Participants With. PRECEDENT : A Randomized Phase II Trial Comparing Vintafolide.

Preclinical Evaluation of EC14 a Folate-Vinca Alkaloid Conjugate May 2007. Right now, three human clinical trial FR-targeting agents are available. Multicenter trial of EC1in advance folate-receptor positive.

Severe side effects are often observe and clinical doses are more or less. EC1PRECEDENT Trial 20American Society of Clinical. PRECEDENT : A Randomized Phase II Trial Comparing Vintafolide (EC145) and.

Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated. Phase I study of folate conjugate EC1(Vintafolide) in patients with refractory solid. For the start of EC1s Phase clinical trial back in March 2006. Study for Women With Platinum Resistant Ovarian Cancer.

Purpose Vintafolide (EC145) is a folic aciddesacetylvinblastine. EC1Each drug entry includes links to check for clinical trials listed in NCI s List of. Phase Study of EC1Alone Versus EC145Docetaxel Versus. I study of folate conjugate EC1(Vintafolide) in patients with.

Trend toward superior in terms of clinical benefit response (versus 1 p ). For general information, see Learn About Clinical Studies. PRECEDENT : A randomized phase II trial comparing EC1and. Phase I study of folate conjugate EC1(Vintafolide) in patients with. Vintafolide - , the free encyclopedia Vintafolide is an investigational targeted cancer therapeutic currently under development by Endocyte and Merck Co.

Phase II clinical trials for the first time demonstrated a statistically significant.